June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Short-term results of the switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Despréaux Raphaëlle
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
  • Salomon Y Cohen
    Centre Ophtalmologique d'Imagerie et de Laser, Paris, France
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
  • Oudy Semoun
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
  • Olivia Zambrowski
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
  • Camille Yung
    CRC-CRB, Hopital Intercommunal de Créteil, Créteil, France
  • Hassiba Oubraham
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
  • Eric H Souied
    Ophthalmology, Hopital Intercommunal de Créteil, Créteil, France
    CRC-CRB, Hopital Intercommunal de Créteil, Créteil, France
  • Footnotes
    Commercial Relationships Despréaux Raphaëlle, None; Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Théa (C); Oudy Semoun, None; Olivia Zambrowski, None; Camille Yung, None; Hassiba Oubraham, Allergan (C), Bayer (C), Novartis (C); Eric Souied, Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4586. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Despréaux Raphaëlle, Salomon Y Cohen, Oudy Semoun, Olivia Zambrowski, Camille Yung, Hassiba Oubraham, Eric H Souied; Short-term results of the switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4586.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Several studies have documented the switch from ranibizumab to aflibercept in patients with refractory choroidal neovascularization due to neovascular age-related macular degeneration (nAMD). In case of limited results of the switch, some patients may be switched back to the initially prescribed drug. We conducted a retrospective study to determine the short-term efficacy of switching back from aflibercept to ranibizumab in nAMD patients previously switched from ranibizumab to aflibercept.

Methods: Double-center retrospective study of 47 eyes of 45 nAMD patients first treated with ranibizumab then aflibercept and retreated with ranibizumab was performed. Primary outcome was changes in best-corrected visual acuity (BCVA) measured using the ETDRS chart before (T0) and after (T1) switching, and three months after switching back (T2). Secondary outcomes were changes in central foveal thickness (CFT) on SD-OCT between T0, T1 and T2, and percentage of patients who gained ≥ 5 letters.

Results: Mean BCVA was 67.4±13.4 at T0, 66.7±14.4 at T1, and 68.2±13.9 at T2. BCVA significantly improved between T1 and T2 (p=0.02), but not between T0 and T1 (p=0.51) and T0 and T2 (p=0.42). Mean CFT decreased from 317.8±89.6 μm at T0 to 306.9±68.0 μm at T1<br /> and 291.2±76.6 μm at T2. CFT did not significantly decrease between T0 and T1 and T1 and T2, but significantly decreased between T0 and T2 (p=0.002). Thirteen eyes gained ≥ 5 letters after switching back.

Conclusions: Switching back from aflibercept to ranibizumab resulted in short-term benefits in nAMD patients for whom switching from ranibizumab to aflibercept was weakly effective.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×